GlaxoSmithKline

The global cancer gene therapy market is projected to grow from USD 1,822.2 million in 2024 to USD 3,142.2 million by 2034, driven by increased R&D funding, rising cancer prevalence, and favorable government regulations. Oncolytic virotherapy, a key segment, generated USD 850.7 million in 2023. The market is shifting towards personalized, targeted therapies, reducing side effects and improving outcomes.

K.W. is a member of the ACTIVE Workgroup supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. J.L.M., B.P.L., and M.C.M. are consultants for GlaxoSmithKline, Novo Nordisk, HepaTX, and Prodigy. M.C.M. also serves on the Board of Amygdala Neuroscience and receives research support from Durect. Other authors declare no competing interests.

iTeos Therapeutics Inc. (ITOS) has several clinical milestones for its lead drug candidate, Belrestotug, including phase III and II trials for non-small cell lung cancer and head and neck squamous cell carcinoma. Interim data from the GALAXIES Lung-201 trial is expected in the second half of this year, with topline data from the phase I trial of EOS-984 also anticipated in the same period. The company ended June 30, 2024, with $679.4 million in cash, cash equivalents, and investments.

GSK announces positive phase III ANCHOR trials results for depemokimab in chronic rhinosinusitis with nasal polyps, showing significant reduction in nasal polyp size and nasal obstruction at 52 weeks. Depemokimab, an ultra-long-acting biologic, is administered once every six months, targeting IL-5, a key cytokine in type 2 inflammation.

GSK's depemokimab showed positive results in late-stage trials for chronic rhinosinusitis with nasal polyps, affecting up to 4% of the population. The drug, an ultra-long acting injection, is expected to launch between 2026-2027, potentially generating up to £3 billion annually.

GSK announced positive Phase 3 ANCHOR-1 and ANCHOR-2 results for depemokimab in chronic rhinosinusitis with nasal polyps (CRSwNP), meeting primary endpoints of reduced nasal polyp size and obstruction. Adverse events were similar to placebo. Data from these and SWIFT studies will support global regulatory filings.

Ian Lyall, Managing Editor at Proactive, oversees editorial and broadcast operations across six offices, directing 50,000 pieces of content annually. Proactive provides global investment news, spanning key finance hubs, focusing on medium and small-cap markets, and covering sectors like biotech, mining, and crypto. The team uses technology to enhance workflows, ensuring human-authored content.

GSK's depemokimab met main objectives in Phase 3 trials, showing efficacy for chronic rhinosinusitis with nasal polyps, with significant reduction in polyp size and nasal obstruction. Adverse event incidence and severity were similar to placebo. GSK plans regulatory filings using trial results.

The article contains a PDF file structure with metadata and viewer preferences.

GSK announces positive results from phase III trials ANCHOR-1 and ANCHOR-2, showing depemokimab significantly reduces nasal polyp size and nasal obstruction in CRSwNP patients. Depemokimab, an ultra-long-acting biologic, targets IL-5 and could be dosed every six months, potentially improving treatment for type 2 inflammatory conditions. Full results to be presented at a scientific congress.